Iva Gueorguieva

Iva Gueorguieva

Auto-generated profile, based on publicly available information

Iva Gueorguieva

Pediatric Endocrine Unit, CHU Lille, Univ Lille, Lille, France.

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Joint Bone Spine
Verified
Journal Article
Closed access
JBJustine Bacchetta
Justine Bacchetta
ARAnya Rothenbuhler
Anya Rothenbuhler
IGIva Gueorguieva
Iva Gueorguieva
PKPeter Kamenicky
Peter Kamenicky
Jean Pierre SallesJean Pierre Salles
Jean Pierre Salles
ALAgnes Linglart
Agnes Linglart

13 October 2023 in European Journal of Endocrinology
Verified
Journal Article
Closed access
PDF file
EBEmese Boros
Emese Boros
DEDiana-Alexandra Ertl
Diana-Alexandra Ertl
JBJugurtha Berkenou
Jugurtha Berkenou
CAChristelle Audrain
Christelle Audrain
ALAnne Lise Lecoq
Anne Lise Lecoq
ARAnya Rothenbuhler
Anya Rothenbuhler
Objectives: The aim of this study is to analyze height after cessation of growth (final height [FH]) and its evolution over the last decades in X-linked hypophosphatemia (XLH) patients in France, as the data on natural history of FH in XLH are lacking. Design: We performed a retrospective observational study in a large cohort of French XLH patients with available data on FH measurements. Materials and methods: We divided patients into 3 groups according to their birth year: group 1 born between 1950 and 1974, group 2 born between 1975 and 2000, and group 3 born between 2001 and 2006, respectively, and compared their FHs. Results: A total of 398 patients were included. Mean FHs were the following: for group 1, −2.31 ± 1.11 standard deviation score (SDS) (n = 127), 156.3 ± 9.7 cm in men and 148.6 ± 6.5 cm in women; for group 2, −1.63 ± 1.13 SDS (n = 193), 161.6 ± 8.5 cm in men and 153.1 ± 7.2 cm in women; and for group 3, −1.34 ± 0.87 SDS (n = 78), 165.1 ± 5.5 cm in men and 154.7 ± 6 cm in women. We report a significant increase in mean FH SDS over 3 generations of patients, for both men and women (P < .001). Final height SDS in male (−2.08 ± 1.18) was lower than in female (−1.70 ± 1.12) (P = .002). Conclusion: The FH of XLH patients in France increased significantly over the last decades. Even though men's FHs improved more than women's, men with XLH remain shorter reflecting a more severe disease phenotype. While the results are promising, most patients with XLH remain short leaving room for improvement.

30 August 2025 in JBMR Plus
Verified
Journal Article
Open access
ALAgnes Linglart
Agnes Linglart
CACyril Amouroux
Cyril Amouroux
IGIva Gueorguieva
Iva Gueorguieva
JHJerome Harambat
Jerome Harambat
JSJean-Pierre Salles
Jean-Pierre Salles
JBJustine Bacchetta
Justine Bacchetta
X-linked hypophosphatemia (XLH) is a phosphate-wasting disorder caused by increased fibroblast growth factor 23 (FGF23); it leads to skeletal deformities, muscle weakness, and pain. In a pediatric phase 3 trial, the FGF23 inhibitor burosumab improved rickets severity and bone biochemistry. The current study characterizes health-related quality of life (HRQL) in children with XLH using real-world data collected at centers in France for the International XLH Registry from April 2017 to January 2024. Age-appropriate versions of the Pediatric Quality of Life Inventory were completed. Data from the first completion after registry entry were analyzed. Variation in scores by demographic, medical history, and treatment history variables was assessed using bivariate analysis. The data were collected from 96 children (59% female; mean age 8.1 [SD 4.4] yr); 82% were taking burosumab. Mean total, summary, and domain scores were similar in different age groups. Mean total score (74.2 [SD 14.1]), Psychosocial Health Summary (72.0 [16.8]), and Physical Health Summary (78.3 [12.3]) scores were lowest in patients aged 5-7 yr and highest in patients aged 13-17 yr (81.0 [13.3], 79.8 [14.1], and 83.1 [15.2]). The mean Psychosocial Health Summary score was lower than the Physical Health Summary score for all patients combined (77.8 [13.9] vs 81.7 [14.3]). Better total scores were associated with not currently taking phosphate/vitamin D analogs, better Psychosocial Health Summary scores with higher serum phosphate and not taking phosphate/vitamin D analogs, and better Physical Health Summary scores with lower serum PTH and currently taking burosumab. Patients with XLH who were taking burosumab at the time of PedsQL completion had better total and summary scores than children with other chronic musculoskeletal disorders. Children aged 5-7 yr had worse HRQL than a healthy Dutch sample. Overall, better HRQL was associated with higher serum phosphate levels and burosumab treatment.

9 May 2025 in Journal of the Endocrine Society
Verified
Journal Article
Open access
IRInes Ben Rhaiem
Ines Ben Rhaiem
JBJacques Beltrand
Jacques Beltrand
GVGaëlle Vermillac
Gaëlle Vermillac
DKDulanjalee Kariyawasam
Dulanjalee Kariyawasam
DGDelphine Geraud
Delphine Geraud
MPMichel Polak
Michel Polak
Context: Neonatal diabetes mellitus (NDM) is a rare condition usually related to an identifiable genetic cause. Sulfonylurea therapy can ensure metabolic control, obviating the need for insulin while also improving neurodevelopmental outcomes. An oral glyburide suspension (OGS; AMGLIDIA) designed for pediatric use was introduced recently to eliminate the drawbacks of using crushed tablets. Objective: To evaluate the long-term effectiveness and safety of the OGS for NDM. Design: Retrospective cohort study. Setting: Fifteen centers in France. Patients: Consecutive patients started on OGS for NDM in 2015 through 2024. Intervention: OGS therapy. Main outcome measures: Glycated hemoglobin (HbA1c) values during OGS therapy; growth; and serious adverse events. Results: Of 27 patients, 22 had KCNJ11 mutations, 4 had ABCC8 mutations, and 1 had a 6q24 anomaly. Median follow-up during OGS therapy was 2.7 years (range, 2 months–9 years). At baseline, median HbA1c was 6.5% (5.8–7.9) overall and 6.5%, 6.4%, and 8.9% in the KCNJ11, ABCC8, and 6q24 subgroups, respectively. The median starting glyburide dose was 0.15 mg/kg/day (range, 0.1-0.185). HbA1c decreased nonsignificantly over time in all subgroups (P = .382), prompting in a small OGS dosage decrease. The last recorded HbA1c value was 6.3%, 5.9%, and 7.4% in the KCNJ11, ABCC8, and 6q24 subgroups, respectively. Serious adverse events were rare, with hypoglycemia in 2 patients during periods of decreased food intake and diarrhea in 1 patient. Conclusion: The OGS was effective in maintaining excellent metabolic control in the long term. The safety profile was good. The OGS should be considered for the first-line treatment of NDM.

22 December 2022 in Cancers
Verified
Journal Article
Open access
PDF file
CPColine Puvilland
Coline Puvilland
CBCarine VILLANUEVA BOUANANI
Carine VILLANUEVA BOUANANI
AHAnaëlle Hemmendinger
Anaëlle Hemmendinger
LKLaure Kornreich
Laure Kornreich
IGIva Gueorguieva
Iva Gueorguieva
PLPierre LEBLOND
Pierre LEBLOND
There is little scientific evidence regarding the safety of GHRT in LGG, where GH deficiency is common. Purpose: to compare the recurrence rate in children with midline LGG, depending on whether or not they have received GHRT, in order to assess its impact on the risk of tumor recurrence. Methods: This bicentric retrospective study included 124 patients under the age of 18 who were diagnosed with a midline low-grade glial tumor between 1998 and 2016. We also reviewed literature on this subject. The main outcome measure was tumor relapse, demonstrated by brain MRI. Results: There were 17 patients in the GH-supplemented group (14%) and 107 patients in the non-supplemented group (86%). Relapse occurred in 65 patients (45.5%); 7 patients died (4.9%); no deaths occurred in patients receiving GHRT. Two patients developed a second tumor (1.4%), none of which had received GHRT. Relapse concerned 36.4% of patients without GHRT and 52.9% of patients with GHRT. The difference was not statistically significant between the two groups (p = 0.3). Conclusion: GHRT does not lead to a statistically significant increase in risk of relapse for pediatric midline low-grade pediatric glioma in our cohort. Although these results appear reassuring, future natural history or prospective studies should be done to ascertain these findings. Nevertheless, these reassuring data regarding GHRT are in agreement with the data in the current literature.

20 March 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
VSVrinda Saraff
Vrinda Saraff
PSPedro Arango Sancho
Pedro Arango Sancho
JBJustine Bacchetta
Justine Bacchetta
ABAnnemieke M. Boot
Annemieke M. Boot
CBChristine Burren
Christine Burren
ALAgnès Linglart
Agnès Linglart
X-linked hypophosphataemia is a rare, genetic, lifelong disorder caused by phosphate-regulating endopeptidase homologue X-linked pathogenic variants and, if left untreated, is associated with a progressive accumulation of musculoskeletal manifestations. Burosumab is a fully human monoclonal antibody that targets circulating fibroblast growth factor 23 and directly inhibits its activity, thereby correcting the abnormal phosphate homoeostasis in people with X-linked hypophosphataemia (XLH). The efficacy and safety of burosumab has been demonstrated in a programme of clinical trials in children and adults. Few data describe the experience of adolescents with XLH receiving burosumab treatment before and after skeletal growth ends. This prospective, multicentre, mixed-methods study described the lived experience of adolescents with XLH treated with burosumab at the end of skeletal growth (NCT05181839). Using patient-reported outcomes, wearable devices, and interviews, we found low median symptom severity scores for pain (0.00), stiffness (0.00), and fatigue (1.75) on a 0–10 scale. Symptoms were usually triggered by physical activity but rarely interfered with daily life. Some adolescents reported emotional concerns related to XLH and treatment transition. These insights can inform patient support during transition to adult care.